ArticleMolecular oncology2026
Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation.
Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Although microwave ablation (MWA) constitutes an effective targeted treatment for liver cancer, the mechanisms driving high recurrence rates remain poorly understood. To elucidate these processes, we established an incomplete MWA (iMWA) model in rabbit VX2 tumors and conducted proteomic profiling of residual tumors at Days 3 (D3) and 14 (D14) postablation. By integrating genomic profiles from mouse radiofrequency ablation (RFA) models, we identified 81 and 92 upregulated proteins at D3 and D14, respectively. Functional enrichment analysis (STRING and Enrichr) revealed acute injury response and extracellular matrix (ECM) remodeling predominating at D3, then markedly declining by D14. Conversely, pathways associated with signal transduction, tumorigenesis, and immune pathways were substantially upregulated at D14. Specifically, protein-protein interaction (PPI) analysis revealed that macrophage remodeling and immune checkpoint networks are functionally coupled at D14 to orchestrate an immunosuppressive microenvironment. Stouffer analysis confirmed the shift from matrix remodeling at an early stage to late-stage oncogenic signal transduction and immune suppression at progression. Overall, these findings characterize the dynamic mechanisms of postablation residual tumor growth and highlight potential therapeutic targets to inhibit protumorigenic pathways while enhancing antitumor immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.